These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23584117)

  • 21. Alcoholism and neuropeptides: an update.
    Cowen MS; Lawrence AJ
    CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):233-9. PubMed ID: 16611096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Heilig M; Egli M
    Pharmacol Ther; 2006 Sep; 111(3):855-76. PubMed ID: 16545872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.
    Schwandt ML; Cortes CR; Kwako LE; George DT; Momenan R; Sinha R; Grigoriadis DE; Pich EM; Leggio L; Heilig M
    Neuropsychopharmacology; 2016 Nov; 41(12):2818-2829. PubMed ID: 27109623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.
    Milivojevic V; Angarita GA; Hermes G; Sinha R; Fox HC
    Alcohol Clin Exp Res; 2020 Jul; 44(7):1488-1496. PubMed ID: 32449942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors.
    Kissler JL; Sirohi S; Reis DJ; Jansen HT; Quock RM; Smith DG; Walker BM
    Biol Psychiatry; 2014 May; 75(10):774-82. PubMed ID: 23611261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs for relapse prevention of alcoholism: ten years of progress.
    Spanagel R; Kiefer F
    Trends Pharmacol Sci; 2008 Mar; 29(3):109-15. PubMed ID: 18262663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.
    Bruchas MR; Land BB; Chavkin C
    Brain Res; 2010 Feb; 1314():44-55. PubMed ID: 19716811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protracted withdrawal from ethanol and enhanced responsiveness stress: regulation via the dynorphin/kappa opioid receptor system.
    Gillett K; Harshberger E; Valdez GR
    Alcohol; 2013 Aug; 47(5):359-65. PubMed ID: 23731692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats.
    Gilpin NW; Richardson HN; Koob GF
    Alcohol Clin Exp Res; 2008 Sep; 32(9):1535-42. PubMed ID: 18631323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alcohol, stress, and glucocorticoids: From risk to dependence and relapse in alcohol use disorders.
    Blaine SK; Sinha R
    Neuropharmacology; 2017 Aug; 122():136-147. PubMed ID: 28159647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain-specific inactivation of the Crhr1 gene inhibits post-dependent and stress-induced alcohol intake, but does not affect relapse-like drinking.
    Molander A; Vengeliene V; Heilig M; Wurst W; Deussing JM; Spanagel R
    Neuropsychopharmacology; 2012 Mar; 37(4):1047-56. PubMed ID: 22113086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic mechanisms of alcoholism and stress-related disorders.
    Palmisano M; Pandey SC
    Alcohol; 2017 May; 60():7-18. PubMed ID: 28477725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.
    Zhou Y; Kreek MJ
    Brain Res; 2019 Dec; 1724():146410. PubMed ID: 31469985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rats on the grog: novel pharmacotherapies for alcohol craving.
    McGregor IS; Gallate JE
    Addict Behav; 2004 Sep; 29(7):1341-57. PubMed ID: 15345269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging pharmacotherapies for alcohol use disorder.
    Mason BJ
    Neuropharmacology; 2017 Aug; 122():244-253. PubMed ID: 28454983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future pharmacotherapy for post-traumatic stress disorder: prevention and treatment.
    Friedman MJ
    Psychiatr Clin North Am; 2002 Jun; 25(2):427-41. PubMed ID: 12136508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Place of the opioid system in biology and treatment of Alcohol Use Disorder].
    Nubukpo P
    Encephale; 2014 Dec; 40(6):457-67. PubMed ID: 25454364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurocircuitry targets in ethanol reward and dependence.
    Koob GF; Roberts AJ; Schulteis G; Parsons LH; Heyser CJ; Hyytiä P; Merlo-Pich E; Weiss F
    Alcohol Clin Exp Res; 1998 Feb; 22(1):3-9. PubMed ID: 9514280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent patents on pharmacotherapy for alcoholism.
    Nagy J
    Recent Pat CNS Drug Discov; 2006 Jun; 1(2):175-206. PubMed ID: 18221202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.